Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies, Inc. (TSHA)
:TSHA
TSHA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $3.31
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.91M
Market Cap
$807.47M
Enterprise Value$435.32M
Total Cash (Recent Filing)$312.76M
Total Debt (Recent Filing)$16.81M
Price to Earnings (P/E)―
Beta2.78
Next Earnings
Nov 12, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding272,794,900
10 Day Avg. Volume3,307,102
30 Day Avg. Volume2,908,091
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue53.76
Enterprise Value/Gross Profit55.66
Enterprise Value/Ebitda-4.75
Forecast
1Y Price Target
$8.73Price Target Upside193.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Clinical TrialsA 100% responder rate was achieved in Part A of the study, increasing confidence in a positive pivotal outcome.
Commercial PotentialTSHA-102 represents an attractive commercial opportunity for the company given promising signs of clinical efficacy and a clear path to approval.
Financial StabilityThe company ended the financial period with $313 million after a substantial financing, indicating strong financial backing.
Bears Say
Competitive RisksCompetitors could prove difficult to beat out, and Astellas has the exclusive option to buy the program, which could limit upside.
Market RisksThere are several risks to the Buy thesis, including long-term efficacy and safety needing validation, public skepticism about gene therapy, and potential competition from other companies.
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies, Inc.’s price range in the past 12 months?
Taysha Gene Therapies, Inc. lowest stock price was $1.05 and its highest was $3.31 in the past 12 months.
What is Taysha Gene Therapies, Inc.’s market cap?
Taysha Gene Therapies, Inc.’s market cap is $807.47M.
When is Taysha Gene Therapies, Inc.’s upcoming earnings report date?
Taysha Gene Therapies, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 76 days.
How were Taysha Gene Therapies, Inc.’s earnings last quarter?
Taysha Gene Therapies, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.078 by -$0.012.
Is Taysha Gene Therapies, Inc. overvalued?
According to Wall Street analysts Taysha Gene Therapies, Inc.’s price is currently Undervalued.
Does Taysha Gene Therapies, Inc. pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
What is Taysha Gene Therapies, Inc.’s EPS estimate?
Taysha Gene Therapies, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. has 272,794,900 shares outstanding.
What happened to Taysha Gene Therapies, Inc.’s price movement after its last earnings report?
Taysha Gene Therapies, Inc. reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.078. Following the earnings report the stock price went up 5.435%.
Which hedge fund is a major shareholder of Taysha Gene Therapies, Inc.?
Currently, no hedge funds are holding shares in TSHA
Taysha Gene Therapies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.73 (193.94% Upside)
$8.73 (193.94% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 18.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 23.9%
Last 30 Days ▲ 23.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.78%
12-Months-Change
Fundamentals
Return on Equity
-51.86%
Trailing 12-Months
Asset Growth
66.34%
Trailing 12-Months
Company Description
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
TSHA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates strong progress in clinical trials, financial stability, and regulatory alignment, suggesting a positive trajectory for Taysha Gene Therapy. However, increased expenses and net loss present financial challenges.View all TSHA earnings summariesTSHA Stock 12 Month Forecast
Average Price Target
$8.73
▲(193.94% Upside)
Technical Analysis
Cartesian Therapeutics
―
Olema Pharmaceuticals
―
Monte Rosa Therapeutics
―
2seventy bio
―
MBX Biosciences, Inc.
―
Ownership Overview
12.52% Insiders
9.10% Mutual Funds
56.49% Other Institutional Investors
14.16% Public Companies and
Individual Investors